# Opus Genetics, Inc. (IRD) stock: price and valuation

URL: https://funkfolio.com/stock/IRD

> Opus Genetics, Inc. (IRD) trades at $4.05, is worth $391.45M and scores 22/100. Valuation history, financials and signals.

---

## Opus Genetics, Inc. (IRD)

Opus Genetics, Inc. (IRD) is a healthcare company (biotechnology) based in the United States. The share price is $4.05, up 0.25% on the day, which values the company at $391.45M. Price as of 18 Nov 2026, 10:24 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $4.05 +0.25% today
- **Market value:** $391.45M
- **Funk Score:** 22/100
- **Against its own history:** Well above its usual price usual price $0.70
- **200-week average:** $2.68 51% above
- **Sector:** Healthcare

Figures as of 18 Nov 2026, 10:24 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Opus Genetics, Inc. in more detail

IRD trades at -5.3× next year's expected earnings, 49.5× sales. Measured against its own history, the price is 481% above what its usual multiples would imply ($0.70) — well above its usual price. It sits 51% above its 200-week average of $2.68.

Its Funk Score is 22 out of 100 (financial strength 3.6, profitability 2.8, growth 2.5, value 0.0, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

### Opus Genetics, Inc. (IRD): questions and answers

**What is Opus Genetics, Inc.'s market cap?**

Opus Genetics, Inc. is valued at $391.45M at a share price of $4.05.

**Is IRD overvalued or undervalued?**

Against its own history, IRD is well above its usual price: the price is 481% above the $0.70 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is IRD above its 200-week moving average?**

Yes. IRD is 51.1% above its 200-week average of $2.68. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Opus Genetics, Inc. growing?**

Over the last three fiscal years Opus Genetics, Inc.'s revenue grew -29.1% a year.

**Does IRD pay a dividend?**

Opus Genetics, Inc. does not currently pay a regular dividend.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Opus Genetics, Inc. (IRD) stock: price, valuation and fundamentals”, data as of 18 November 2026. https://funkfolio.com/stock/IRD

Underlying data: Yahoo Finance; company filings with the SEC.
